Intellia Therapeutics (NTLA) Cash from Investing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Cash from Investing Activities for 12 consecutive years, with $66.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 29.7% year-over-year to $66.3 million; the TTM figure through Mar 2026 stood at $200.0 million (down 6.53% YoY), while the FY2025 annual figure was $228.0 million, up 81.6% from the prior year.
• Cash from Investing Activities improved to $66.3 million in Q1 2026 per NTLA's latest filing, from $27.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $151.6 million in Q4 2024 and bottomed at -$122.2 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged $32.3 million across 5 years, with a median of $45.9 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 357.51% — and 2025, when it surged 1498.51%.
• Intellia Therapeutics' Cash from Investing Activities stood at -$30.2 million in 2022, then surged by 252.36% to $45.9 million in 2023, then surged by 229.93% to $151.6 million in 2024, then sank by 81.83% to $27.5 million in 2025, then jumped by 140.83% to $66.3 million in 2026.
• Business Quant data shows NTLA's Cash from Investing Activities at $66.3 million in Q1 2026, $27.5 million in Q4 2025, and -$741000.0 in Q3 2025.